Depot-Forming Immunostimulant for Solid Tumors

A tumor immunostimulant product candidate that comprises of a highly potent and selective dual TLR7/8 agonist conjugated to our depot-forming technology to overcome the safety limitations associated with the use of unconjugated immune stimulants. Our depot-forming platform technology can be used to provide localization and improve the safety of a variety of immune stimulants or other therapeutics.  Our approach is to couple the TLR7/8 immunostimulant to our proprietary platform to anchor the immunostimulant at the tumor site for focused immune stimulation. ALT-702 has the potential to synergize with checkpoint inhibitors and other immunotherapeutics and is being evaluated in additional preclinical solid tumor models.

ALT-702 Image